Trial Profile

A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elivaldogene autotemcel (Primary) ; Busulfan; Fludarabine; Plerixafor
Indications Adrenoleucodystrophy
Focus Registrational; Therapeutic Use
Acronyms ALD-104 ALD-104
Sponsors bluebird bio

Most Recent Events

08 Sep 2023 Status changed from active, no longer recruiting to completed.
14 Jun 2023 This trial has been Completed in Italy, according to European Clinical Trials Database record.
02 Jun 2023 This trial has been discontinued in Germany, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com